{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:06:20Z","timestamp":1792551980320,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ccell.2025.03.036","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:42:03Z","timestamp":1745494923000},"page":"1093-1107.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts"],"prefix":"10.1016","volume":"43","author":[{"given":"Jia-Nan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouxia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fancong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Degao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisong Y.","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair L.J.","family":"Symonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-8512","authenticated-orcid":false,"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2025.03.036_bib1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/d41573-019-00167-9","article-title":"Immuno-oncology drug development goes global","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ccell.2025.03.036_bib2","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.03.036_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2025.03.036_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ccell.2023.02.013","article-title":"Mutations in IFN-\u03b3 signaling genes sensitize tumors to immune checkpoint blockade","volume":"41","author":"Song","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.03.036_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41556-021-00820-9","article-title":"Cancer-cell-derived GABA promotes \u03b2-catenin-mediated tumour growth and immunosuppression","volume":"24","author":"Huang","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccell.2025.03.036_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41590-023-01723-7","article-title":"Breaking NGF-TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection","volume":"25","author":"Yin","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molmed.2019.03.003","article-title":"PTEN Mutations Trigger Resistance to Immunotherapy","volume":"25","author":"Cheng","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127901","article-title":"Titin mutation associated with responsiveness to checkpoint blockades in solid tumors","volume":"4","author":"Jia","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ccell.2025.03.036_bib9","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-018-0205-5","article-title":"Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells","volume":"24","author":"Zhao","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib10","first-page":"215","article-title":"Host tissue determinants of tumour immunity","volume":"19","author":"Salmon","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2025.03.036_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2025.03.036_bib12","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder","volume":"34","author":"Massard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.03.036_bib13","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2025.03.036_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2025.03.036_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1030147","article-title":"The effect of organ-specific tumor microenvironments on response patterns to immunotherapy","volume":"13","author":"Conway","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004884","article-title":"Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites","volume":"10","author":"Conway","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ccell.2025.03.036_bib17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/2159-8290.CD-17-1320","article-title":"Tissue-Specific Immunoregulation: A Call for Better Understanding of the \"Immunostat\" in the Context of Cancer","volume":"8","author":"Pao","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2025.03.036_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States","volume":"18","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ccell.2025.03.036_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8970173","article-title":"Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation","volume":"2021","author":"Liu","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ccell.2025.03.036_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ccell.2025.03.036_bib22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2025.03.036_bib23","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.03.036_bib24","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2022.04.018","article-title":"Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1\/PD-L1 treatment efficacy","volume":"40","author":"Long","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2025.03.036_bib25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-019-0178-8","article-title":"Osteoimmunology: evolving concepts in bone-immune interactions in health and disease","volume":"19","author":"Tsukasaki","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib27","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ccell.2025.03.036_bib29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.21037\/tcr-20-2547","article-title":"A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors","volume":"10","author":"Xie","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.ccell.2025.03.036_bib30","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","article-title":"Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer","volume":"9","author":"Jia","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2025.03.036_bib31","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ccell.2025.03.036_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2025.03.036_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2025.03.036_bib34","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2025.03.036_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2025.03.036_bib37","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1210\/jc.2003-030910","article-title":"Clinical review 165: Markers of bone remodeling in metastatic bone disease","volume":"88","author":"Fohr","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ccell.2025.03.036_bib38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1593","article-title":"Skeletal remodeling in health and disease","volume":"13","author":"Zaidi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib39","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.2499","article-title":"Targeting osteoclast-osteoblast communication","volume":"17","author":"Cao","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib40","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ccell.2025.03.036_bib41","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2025.03.036_bib42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbadis.2009.05.004","article-title":"Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions","volume":"1792","author":"Everts","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ccell.2025.03.036_bib43","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1158\/0008-5472.CAN-13-3334","article-title":"Osteopontin shapes immunosuppression in the metastatic niche","volume":"74","author":"Sangaletti","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2025.03.036_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13051006","article-title":"Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression","volume":"13","author":"Klement","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ccell.2025.03.036_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.003","article-title":"The multiple functions and mechanisms of osteopontin","volume":"59","author":"Icer","year":"2018","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ccell.2025.03.036_bib46","first-page":"666","article-title":"Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation","volume":"123","author":"Lotinun","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ccell.2025.03.036_bib47","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.1001230","article-title":"Diversity index of mucosal resident T lymphocyte repertoire predicts clinical prognosis in gastric cancer","volume":"4","author":"Jia","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ccell.2025.03.036_bib48","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.ccell.2025.03.036_bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41423-022-00959-x","article-title":"RANKL-responsive epigenetic mechanism reprograms macrophages into bone-resorbing osteoclasts","volume":"20","author":"Bae","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12967-019-1847-x","article-title":"A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab","volume":"17","author":"Botticelli","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal5081","article-title":"Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF(high) neutrophils","volume":"358","author":"Engblom","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ccell.2025.03.036_bib53","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","article-title":"Radiotherapy Enhances Metastasis Through Immune Suppression by inducing PD-L1 and MDSC in distal sites","volume":"30","author":"Hou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2025.03.036_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10070218","article-title":"The Osteoclast in Bone Metastasis: Player and Target","volume":"10","author":"Maurizi","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ccell.2025.03.036_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cmet.2013.09.014","article-title":"Osteocytes regulate primary lymphoid organs and fat metabolism","volume":"18","author":"Sato","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.ccell.2025.03.036_bib57","article-title":"Osteoclast-derived apoptotic bodies inhibit naive CD8(+) T cell activation via Siglec15, promoting breast cancer secondary metastasis","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ccell.2025.03.036_bib58","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ni.3791","article-title":"Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin","volume":"18","author":"Kanayama","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nri2460","article-title":"Regulation of T-helper-cell lineage development by osteopontin: the inside story","volume":"9","author":"Cantor","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2025.03.036_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110170","article-title":"Secreted osteopontin from CD4(+) T cells limits acute graft-versus-host disease","volume":"37","author":"Aggarwal","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2025.03.036_bib61","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","article-title":"Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade","volume":"68","author":"Zhu","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ccell.2025.03.036_bib62","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1073\/pnas.1221609110","article-title":"T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy","volume":"110","author":"Zhong","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2025.03.036_bib63","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ccell.2025.03.036_bib64","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.21037\/jtd-21-150","article-title":"Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors","volume":"13","author":"Cao","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.ccell.2025.03.036_bib65","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ccell.2025.03.036_bib66","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2020.06.011","volume":"15","author":"Peters","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ccell.2025.03.036_bib67","series-title":"R Development Core Team (2010): R: A language and environment for statistical computing. Computer programme","author":"Dalgaard","year":"2010"},{"key":"10.1016\/j.ccell.2025.03.036_bib68","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2025.03.036_bib69","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ccell.2025.03.036_bib70","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ccell.2025.03.036_bib71","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ccell.2025.03.036_bib72","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.ccell.2025.03.036_bib73","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cels.2018.02.010","article-title":"Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry","volume":"6","author":"Chevrier","year":"2018","journal-title":"Cell Syst."},{"key":"10.1016\/j.ccell.2025.03.036_bib74","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res."},{"key":"10.1016\/j.ccell.2025.03.036_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005112","article-title":"Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline","volume":"12","author":"Chen","year":"2016","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ccell.2025.03.036_bib76","author":"Kremer"},{"key":"10.1016\/j.ccell.2025.03.036_bib77","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.ccell.2025.03.036_bib78","series-title":"factoextra: Extract and Visualize the Results of Multivariate Data Analyses","author":"Kassambara","year":"2020"},{"key":"10.1016\/j.ccell.2025.03.036_bib79","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2025.03.036_bib80","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: An R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res."},{"key":"10.1016\/j.ccell.2025.03.036_bib81","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41592-023-02014-7","article-title":"Extending support for mouse data in the Molecular Signatures Database (MSigDB)","volume":"20","author":"Castanza","year":"2023","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ccell.2025.03.036_bib82","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2025.03.036_bib83","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.1198704","article-title":"Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum","volume":"332","author":"Bendall","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ccell.2025.03.036_bib84","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610825001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:01:53Z","timestamp":1749466913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1535610825001370"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2025.03.036","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2025.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}